[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 609, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 2104473, "exercisedValue": 1024000, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 60, "title": "COO, General Counsel & Secretary", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 998520, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 46, "title": "Chief Medical Officer and Head of R&D", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 897694, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 70, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 70, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy  Davis M.B.A.", "title": "SVP of Cardiovascular & Head of Metabolic Franchise", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 11.35, "open": 11.27, "dayLow": 10.92, "dayHigh": 11.505, "regularMarketPreviousClose": 11.35, "regularMarketOpen": 11.27, "regularMarketDayLow": 10.92, "regularMarketDayHigh": 11.505, "payoutRatio": 0.0, "beta": 0.996, "forwardPE": -2.6635072, "volume": 2367656, "regularMarketVolume": 2367656, "averageVolume": 2103609, "averageVolume10days": 2661920, "averageDailyVolume10Day": 2661920, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 1543442944, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 30.41, "priceToSalesTrailing12Months": 617.3772, "fiftyDayAverage": 15.7852, "twoHundredDayAverage": 20.47665, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1742039808, "profitMargins": 0.0, "floatShares": 108000510, "sharesOutstanding": 137316992, "sharesShort": 11979733, "sharesShortPriorMonth": 9196579, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.0872, "heldPercentInsiders": 0.13092, "heldPercentInstitutions": 0.74875, "shortRatio": 7.13, "shortPercentOfFloat": 0.112799995, "impliedSharesOutstanding": 137316992, "bookValue": 0.419, "priceToBook": 26.825775, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -639713984, "trailingEps": -5.15, "forwardEps": -4.22, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 696.816, "enterpriseToEbitda": -2.873, "52WeekChange": -0.53010035, "SandP52WeekChange": 0.05430484, "quoteType": "EQUITY", "currentPrice": 11.24, "targetHighPrice": 80.0, "targetLowPrice": 21.0, "targetMeanPrice": 45.64286, "targetMedianPrice": 41.5, "recommendationKey": "none", "numberOfAnalystOpinions": 14, "totalCash": 550835008, "totalCashPerShare": 4.368, "ebitda": -606380032, "totalDebt": 872046016, "quickRatio": 5.902, "currentRatio": 6.085, "totalRevenue": 2500000, "debtToEquity": 1555.142, "revenuePerShare": 0.02, "returnOnAssets": -0.47709998, "returnOnEquity": -5.65332, "grossProfits": 2500000, "freeCashflow": -382800256, "operatingCashflow": -491283008, "revenueGrowth": -0.296, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -64.5648, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1744931484, "regularMarketTime": 1744920002, "marketState": "CLOSED", "regularMarketChangePercent": -0.96916837, "regularMarketPrice": 11.24, "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "priceEpsCurrentYear": -3.3880627, "fiftyDayAverageChange": -4.5452003, "fiftyDayAverageChangePercent": -0.28794062, "twoHundredDayAverageChange": -9.23665, "twoHundredDayAverageChangePercent": -0.4510821, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "postMarketChangePercent": 0.533812, "postMarketPrice": 11.3, "postMarketChange": 0.0600004, "regularMarketChange": -0.11000061, "regularMarketDayRange": "10.92 - 11.505", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2103609, "fiftyTwoWeekLowChange": 1.6700001, "fiftyTwoWeekLowChangePercent": 0.17450367, "fiftyTwoWeekRange": "9.57 - 30.41", "fiftyTwoWeekHighChange": -19.17, "fiftyTwoWeekHighChangePercent": -0.63038474, "fiftyTwoWeekChangePercent": -53.010033, "earningsTimestamp": 1739221260, "earningsTimestampStart": 1746615540, "earningsTimestampEnd": 1747051200, "earningsCallTimestampStart": 1739223000, "earningsCallTimestampEnd": 1739223000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -5.15, "epsForward": -4.22, "epsCurrentYear": -3.31753, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-04-19"}]